[Skip to Content]
[Skip to Content Landing]
Viewpoint
March 24/31, 2015

Naltrexone Extended-Release Plus Bupropion Extended-Release for Treatment of Obesity

Author Affiliations
  • 1Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
  • 2Section on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland
 

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(12):1213-1214. doi:10.1001/jama.2015.1617

In September 2014, a proprietary formulation of naltrexone extended-release (ER) plus bupropion-ER (brand name Contrave) was approved by the US Food and Drug Administration (FDA),1 becoming the fourth medication approved for long-term weight management in patients with obesity.2 Liraglutide (brand name Saxenda), a glucagon-like peptide 1 receptor agonist, was also approved for obesity treatment in December 2014. This Viewpoint discusses naltrexone-bupropion ER and its potential use for the adjunctive treatment of patients with obesity.

First Page Preview View Large
First page PDF preview
First page PDF preview
×